(1-methyl-2-phenyl-ethyl)-phosphoramidic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (1-methyl-2-phenyl-ethyl)-phosphoramidic acid
• 英文别名: (1-Phenylpropan-2-ylamino)phosphonic acid
• 化学式: C₉H₁₄NO₃P
• 分子量: 215.189
• InChiKey: VARCULSTPMUWMP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  69.6
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  非那明 在 氰化钠 、 三乙胺 作用下， 以 氯仿 、 二甲基亚砜 为溶剂， 生成 (1-methyl-2-phenyl-ethyl)-phosphoramidic acid
  参考文献：
  名称：

  Thuong,N.T.; Chabrier,P., Bulletin de la Societe Chimique de France, 1975, p. 2083 - 2088

  摘要：

  DOI：

文献信息

• AMPHETAMINE CONTROLLED RELEASE, PRODRUG, AND ABUSE-DETERRENT DOSAGE FORMS
  申请人：CHEMAPOTHECA, LLC

  公开号：US20180243241A1

  公开（公告）日：2018-08-30

  The invention also relates to pharmaceutical compositions comprising highly pure amphetamine and amphetamine-class compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds, and to methods of manufacturing, delivering, and using the amphetamine compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds.

  这项发明还涉及包含高纯度苯丙胺和苯丙胺类化合物的药物组合物，这些化合物是通过对手性和消旋苯丙胺衍生物进行立体特异性、区域选择性的杯酸盐加成反应与环氧乙烷磷酰胺化合物合成而得到的，并且涉及通过对手性和消旋苯丙胺衍生物进行立体特异性、区域选择性的杯酸盐加成反应与环氧乙烷磷酰胺化合物合成而得到的苯丙胺化合物的制造、输送和使用方法。
• [EN] AMPHETAMINE CONTROLLED RELEASE, PRODRUG, AND ABUSE DETERRENT DOSAGE FORMS<br/>[FR] LIBÉRATION CONTRÔLÉE DE L'AMPHÉTAMINE, PROMÉDICAMENT ET FORMES POSOLOGIQUES DISSUASIVES DU MÉSUSAGE
  申请人：CHEMAPOTHECA LLC

  公开号：WO2017147375A1

  公开（公告）日：2017-08-31

  The invention also relates to pharmaceutical compositions comprising highly pure amphetamine and amphetamine-class compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds, and to methods of manufacturing, delivering, and using the amphetamine compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds.

  这项发明还涉及包含高纯度苯丙胺和苯丙胺类化合物的药物组合物，这些化合物是通过对手性和消旋苯丙胺衍生物进行立体特异性、区域选择性的杯酸盐加成反应与环氧乙烷磷酰胺化合物合成的，以及通过对手性和消旋苯丙胺衍生物进行立体特异性、区域选择性的杯酸盐加成反应与环氧乙烷磷酰胺化合物合成的苯丙胺化合物的制造、输送和使用方法。
• Noncardiotoxic pharmaceutical compounds
  申请人：Barbeau L. Donald

  公开号：US20060035863A1

  公开（公告）日：2006-02-16

  The present invention relates to novel noncardiotoxic compounds and pharmaceutical compositions useful in the treatment of a variety of disorders including the treatment of depression, allergies, psychoses, cancer and gastrointestinal disorders. In particular, the present invention describes pharmaceutical compositions that mitigate life-threatening arrhythmias such as torsade de pointes. Torsade de pointes is a particular cardiac problem associated with many therapeutic agents and has been implicated as a possible cause of sudden death, particularly in those individuals with a past history of disturbances of cardiac rhythm, myocardial infarction, congenital repolarization abnormalities and cardiac risk factors such as hyperlipidemia and age. This arrhythmia is a variant of paroxysmal ventricular tachycardia associated with a prolonged QTc interval or prominent U waves on the ECG. Torsade de pointes is potentially lethal because it can progress to ventricular fibrillation, life-threatening arrhythmias or precipitate sudden death.

  本发明涉及新型无心脏毒性化合物和药物组合物，用于治疗包括抑郁症、过敏、精神病、癌症和胃肠道疾病在内的各种疾病。具体而言，本发明描述了可以缓解危及生命的心律失常，例如扭转型尖波。扭转型尖波是与许多治疗剂相关的一种特殊心脏问题，已被指认为可能导致猝死的原因，特别是在那些有心脏节律紊乱、心肌梗死、先天性复极异常和心脏危险因素（如高脂血症和年龄）的个体中。这种心律失常是一种与心电图上QTc间期延长或U波显著的室性心动过速变异有关的心律失常。扭转型尖波有潜在致命性，因为它可能发展为室颤、危及生命的心律失常或引发猝死。
• Novel Chiral Aziridine Phosphoramidate Compounds
  申请人：CHEMAPOTHECA, LLC

  公开号：US20170210768A1

  公开（公告）日：2017-07-27

  The invention includes processes for the synthesis of amphetamine, dexamphetamine, methamphetamine, derivatives of these, including their salts, and novel precursors and intermediates obtained thereby, by synthesizing aziridine phosphoramidate compounds in specified solvents at specified temperatures, and then converting to a novel aryl or aryl-alkyl phosphoramidate precursors using an organometallic compound such as a copper salt, where the novel aryl or aryl-alkyl phosphoramidate precursor is then easily converted to the target compounds using known reactions,

  该发明包括合成苯丙胺、地匹况、甲基苯丙胺及其衍生物（包括它们的盐）的过程，以及通过在指定溶剂中、在指定温度下合成环氧丙烷磷酰胺化合物，然后使用有机金属化合物（如铜盐）转化为新的芳基或芳基-烷基磷酰胺前体物，并使用已知反应将新的芳基或芳基-烷基磷酰胺前体物轻松地转化为目标化合物的过程。
• Methods of Treatment Using Amphetamine Controlled Release, Prodrug, and Abuse Deterrent Dosage Forms
  申请人：CHEMAPOTHECA, LLC

  公开号：US20210030699A1

  公开（公告）日：2021-02-04

  The invention also relates to pharmaceutical compositions comprising highly pure amphetamine and amphetamine-class compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds, and to methods of manufacturing, delivering, and using the amphetamine compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds.

  本发明还涉及制备高纯度苯丙胺及苯丙胺类化合物的药物组合物，该组合物是通过使用手性和消旋苯丙胺衍生物合成，利用具有立体选择性和区域选择性的杯酸铜加成反应与环氧乙烷磷酰胺化合物反应所得到的。本发明还涉及制备、传递和使用通过使用手性和消旋苯丙胺衍生物合成，利用具有立体选择性和区域选择性的杯酸铜加成反应与环氧乙烷磷酰胺化合物反应所得到的苯丙胺类化合物的方法。